发明名称 |
Polyvalent conjugate vaccine for cancer |
摘要 |
This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject. |
申请公布号 |
US9149516(B2) |
申请公布日期 |
2015.10.06 |
申请号 |
US201313951795 |
申请日期 |
2013.07.26 |
申请人 |
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH |
发明人 |
Livingston Philip O.;Ragupathi Govindaswami;Danishefsky Samuel J. |
分类号 |
A61K39/385;A61K39/00 |
主分类号 |
A61K39/385 |
代理机构 |
Law Offices of Albert Wai-Kit Chan, PLLC |
代理人 |
Law Offices of Albert Wai-Kit Chan, PLLC |
主权项 |
1. A method for inducing antibody production in a subject comprising administering an immunogenic composition comprising an adjuvant and antigens comprising MUC1-Tn conjugate, GloboH, TF(c) and at least one antigen selected from the group consisting of GM2, sTn(c) and sialyl Lea, wherein said conjugate and each of said antigens are individually conjugated to a carrier. |
地址 |
New York NY US |